全球乳腺断层合成市场 – 行业趋势及 2031 年预测

乳腺断层合成市场分析和规模

乳房断层合成在乳腺癌筛查中发挥着至关重要的作用，因为它比传统的 2D 乳房 X 线摄影具有多项优势。它为放射科医生提供了乳房组织的详细 3D 图像，减少了可能掩盖异常的重叠结构，尤其是在致密乳房中。这项技术提高了对 2D 扫描可能无法看到的早期癌症和病变的检测能力，从而减少了假阳性和不必要的额外检测。因此，断层合成提高了整体诊断准确性，增加了在最早和最可治疗阶段检测出乳腺癌的机会，从而有可能改善患者的治疗效果。

2023 年全球乳房断层合成市场规模价值 26.1 亿美元，预计到 2031 年将达到 69.9 亿美元，2024 年至 2031 年预测期内的复合年增长率为 13.10%。除了对市场价值、增长率、细分、地理覆盖范围和主要参与者等市场情景的见解外，Data Bridge Market Research 策划的市场报告还包括深度专家分析、患者流行病学、管道分析、定价分析和监管框架。

报告范围和市场细分       

Market Definition

Breast tomosynthesis, also known as 3D mammography, is an advanced imaging technique used for breast cancer screening and diagnosis. It captures multiple images of the breast from different angles, allowing radiologists to reconstruct a 3D image of the breast tissue. This method provides clearer, more detailed views than traditional 2D mammography, reducing the chances of false positives and improving detection of breast abnormalities, especially in dense breast tissue.

Breast Tomosynthesis Market Dynamics

Drivers                                                                                                        

• Growing Consumer Awareness

As awareness increases about the importance of early detection in breast cancer, individuals become more proactive in seeking advanced screening technologies such as tomosynthesis. This heightened awareness is often fueled by media coverage, educational campaigns, and advocacy efforts promoting the benefits of 3D mammography over traditional methods. Patients and healthcare consumers, particularly those with a family history of breast cancer or other risk factors, are increasingly requesting access to more accurate and reliable breast tomosynthesis screening options. This trend boosts demand for tomosynthesis systems and encourages healthcare providers to invest in these technologies to meet patient expectations and improve diagnostic outcomes.

• Rising Incidence of Breast Cancer

As breast cancer rates increase, there is a heightened need for more accurate and reliable screening methods to detect the disease at its earliest stages. Tomosynthesis offers superior imaging capabilities compared to traditional 2D mammography, enhancing the detection of small tumors and lesions that may be missed by conventional methods. This improved sensitivity reduces false negatives and improves overall diagnostic accuracy, thereby supporting early intervention and better treatment outcomes. The growing awareness of breast cancer and the emphasis on early detection further fuel the adoption of tomosynthesis, making it a crucial technology in the fight against breast cancer.

Opportunities

• Increasing Supportive Regulatory Frameworks

Supportive regulatory frameworks ensures safety, efficacy, and accessibility of these advanced medical technologies. Regulatory agencies worldwide, such as the FDA in the U.S. and CE marking in Europe, provide approvals and clearances that validate the use of tomosynthesis systems for clinical applications. Moreover, regulatory support facilitates reimbursement policies from healthcare payers, making it financially feasible for healthcare facilities to offer tomosynthesis screenings. This regulatory backing thus accelerates market growth by creating a conducive environment for innovation, adoption, and integration into routine clinical practice.

• Expansion of Healthcare Infrastructure

As countries invest in developing and upgrading healthcare facilities, there is an increased capacity and capability to adopt advanced medical technologies such as tomosynthesis. This expansion includes the establishment of new hospitals, clinics, and diagnostic centers equipped with modern imaging equipment. Improved access to healthcare services in both urban and rural areas enhances the reach of breast cancer screening programs utilizing tomosynthesis. Infrastructure development often involves training healthcare professionals on the use of new technologies, fostering greater adoption and integration of tomosynthesis into routine clinical practice.

Restraints/Challenges

• High Cost Of breast Tomosynthesis Machine

High breast tomosynthesis cost are expensive to purchase, install, and maintain, requiring substantial upfront investment from healthcare facilities. The cost burden is further compounded by ongoing expenses for training personnel, upgrading software, and ensuring compliance with regulatory standards. This financial barrier limits adoption rates, especially in healthcare settings with constrained budgets or in regions with lower healthcare expenditure. Additionally, the return on investment timeline for these high-cost systems can be lengthy, deterring some facilities from upgrading or investing in tomosynthesis technology.

• Growing Technological Complexity

The operation and interpretation of tomosynthesis systems require specialized training for radiologists and technicians, which can be time-consuming and costly. This complexity may deter healthcare facilities from adopting the technology, especially in regions with limited access to training programs or skilled personnel. Moreover, integrating tomosynthesis into existing workflow and IT systems can be challenging, leading to potential disruptions and inefficiencies. As a result, the learning curve and initial investment required to implement tomosynthesis may hinder its widespread adoption, particularly in smaller or less advanced healthcare settings.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In August 2022, Whiterabbit launched ACT software in August 2022, designed to automate the analysis of digital breast tomosynthesis images (3D mammograms) for diagnosing breast cancer. This innovation aims to enhance diagnostic accuracy and efficiency by leveraging advanced algorithms for image interpretation
• In May 2022, Therapixel secured EUR 15 million in Series B funding. This investment was intended to bolster the company's commercial expansion efforts in the U.S. It also aimed to further develop their MammoScreen platform, enhancing its capabilities as a reading aid for mammography. The funding underscored investor confidence in Therapixel's technology and growth potential in the medical imaging market
• In January 2021, Hologic expanded its ultrasound portfolio in January 2021 with the introduction of the SuperSonic MACH 20 ultrasound machine. This system integrated advanced features including high-resolution B-mode imaging and ShearWave PLUS elastography in 3D volumes. The innovation was targeted at improving diagnostic accuracy and expanding the applications of ultrasound imaging, particularly in Europe where it was expected to see rapid adoption

Breast Tomosynthesis Market Scope

The market is segmented on the basis of product, and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product

• 2D/3D Combination Systems
• Standalone 3D Systems

End User

• Hospitals
• Diagnostic Centres
• Others

Breast Tomosynthesis Market Regional Analysis/Insights

The market is analysed and market size insights and trends are provided by country, product and end user as referenced above.

The countries covered in the market report are U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America.

North America dominates the market due to increasing incidence of breast cancer. This advanced imaging technology allows for clearer and more accurate detection of breast abnormalities, thus improving diagnostic outcomes. Additionally, despite rising healthcare costs, the demand for more effective diagnostic tools is pushing market expansion further. These factors are expected to sustain robust growth in the digital breast tomosynthesis market across North America.

亚太地区市场预计将出现大幅增长，因为先进医疗技术的采用率不断提高，医疗支出不断上升是主要驱动因素。主要参与者在该地区新兴经济体中扩大业务，提高了市场渗透率。此外，人们对乳腺癌早期检测意识的增强和医疗基础设施的改善进一步促进了亚太地区的市场扩张。这些动态共同将该地区定位为数字乳腺断层合成市场未来增长的关键区域。

报告的国家部分还提供了影响单个市场因素和国内市场监管变化，这些因素和变化会影响市场的当前和未来趋势。下游和上游价值链分析、技术趋势和波特五力分析、案例研究等数据点是用于预测单个国家市场情景的一些指标。此外，在提供国家数据的预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的大量或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。

竞争格局和乳腺断层合成市场分析

市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对市场的关注有关。

市场上的一些主要参与者包括：

• 西门子（德国）
• Hologic 公司（马萨诸塞州）
• 深圳迈瑞生物医疗电子股份有限公司 (中国)
• 雅培（美国）
• BD（新泽西州）
• F. Hoffmann-La Roche Ltd（瑞士）
• 赛默飞世尔科技公司（美国）
• Koninklijke Philips NV（荷兰）
• 岛津医疗（印度）私人有限公司（日本）
• 通用电气（美国）
• Quest Diagnostics Incorporated（美国）
• 希森美康印度列兵。株式会社（日本）
• 日立有限公司（日本）
• 佳能公司（日本）
• 富士胶片控股公司（英国）

SKU-68233